Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aggressive empiric antibiotic therapy versus meropenem alone for mechanically ventilated pneumonia
2012-003483-46Phase 3Terminated
- Sponsor
- University of Florida
- Start
- Sep 2013
- Modality
- Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label trial of meropenem, gentamicin, amikacin and tobramycin in bacterial pneumonia, hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) and 1 more (2 arms), sponsored by University of Florida. Primary endpoint: Suppression of emergence of resistance. Started Sep 2013; status: terminated.
02
Drugs
meropenemgentamicinamikacintobramycin
03
Conditions
bacterial pneumoniahospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)Healthcare-associated pneumonia (HCAP)
Beyond the preview
Go deeper on 2012-003483-46.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003483-46.